Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shares Jump 22 Percent After CEO Said Positive Cash Flow Likely

NEW YORK, July 13 (GenomeWeb News) - Shares in Transgenomic were up 22 percent, or $.17, at $.94 in late-afternoon trading after the company's CEO said the firm "should" reach neutral to positive operating cash flow by the end of the year.


Speaking to investors at Transgenomic's annual shareholder meeting today, Collin D'Silva said the company's recently completed restructuring will help the company "accelerate" revenue growth during the second half of the year, which he said would "approach" 20 percent on a year-over-year basis.

As GenomeWeb News reported last November, Transgenomic restructured its business and exited the oligonucleotide-manufacturing space in order to focus on its BioSystems segment.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.